Maternal plasma Elabela levels in intrauterine growth restriction

Year 2021, , 1344 - 1350, 30.12.2021

Filiz Alkan Baylan , Selim Karaküçük

https://doi.org/10.17826/cumj.976828

Cited By: 1

Abstract

Purpose: The aim of this study was to investigate the role of Elabela in the etiopathogenesis of intrauterine growth retardation (IUGR).
Materials and Methods: The present prospective study included 43 healthy pregnant women and 46 pregnant women with IUGR. Maternal serum were collected from the control group and IUGR group at time of delivery. Elabela levels were analyzed in maternal serum through ELISA method.
Results: Lower Elabela levels (IUGR: 1.09 (0.61-15.61) ng / mL and Control: 1.44 (0.37-31.33) ng / mL) were observed in IUGR patients compared to controls. Elabela levels were positively correlated with gestational week and neonatal weight. (r = 0.263, p = 0.013 and r = 0.259, respectively; p = 0.014).
Conclusion: The present study serves as the first study revealing the role of the decrease in Elabela in maternal serum on the etiopathogenesis of IUGR. This suggests that Elabela could be a potential drug target in cases with IUGR.

Keywords

intrauterine growth restriction, Elabela, Pregnancy

İntrauterin gelişme geriliğinde maternal serum Elabela düzeyleri

Abstract

Amaç: Bu çalışmanın amacı, Elabela'nın intrauterin büyüme geriliğinin (IUGR) etyopatogenezindeki rolünü araştırmaktı.
Gereç ve Yöntem: Bu prospektif çalışmaya 43 sağlıklı gebe ve 46 IUGR'li gebe dahil edildi. Kontrol grubundan ve IUGR grubundan doğum sırasında anneden kan alındı. Elabela seviyeleri anne serumunda ELISA yöntemi ile analiz edildi.
Bulgular: Kontrollere kıyasla IUGR hastalarında daha düşük Elabela seviyeleri (IUGR: 1.09 (0.61-15.61) ng/mL ve Kontrol: 1.44 (0.37-31.33) ng/mL) gözlendi. Elabela seviyeleri, gebelik haftası ve yenidoğan ağırlığı ile pozitif korelasyon gösterdi. (sırasıyla r = 0.263, p = 0.013 ve r = 0.259; p = 0.014).
Sonuç: Bu çalışma, anne serumunda Elabela'daki azalmanın IUGR etyopatogenezindeki rolünü ortaya koyan ilk çalışma olma özelliğini taşımaktadır. Bu, Elabela'nın IUGR'li vakalarda potansiyel bir ilaç hedefi olabileceğini düşündürmektedir.

Keywords

İntranuterin Gelişme Geriliği, Elabela, Gebelik

References

• 1. Figueras F, Gratacos E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther 2014;36(2):86–98.
• 2. Hui L, Challis D. Diagnosis and management of fetal growth restriction: the role of fetal therapy. Best Pract Res Clin Obstet Gynaecol 2008;22(1):139–58.
• 3. Sharma D, Shastri S, Farahbakhsh N, Sharma P. Intrauterine growth restriction–part 1. J Maternfetal Neonat Med 2016;29(24):3977–87.
• 4. Kesavan K, Devaskar SU. Intrauterine Growth Restriction: Postnatal Monitoring and Outcomes. Pediatr Clin North Am 2019;66(2):403-23.
• 5. Suhag A, Berghella V. Intrauterine growth restriction (IUGR): etiology and diagnosis. Curr Obstet Gynecol Rep 2013;2:102–11.
• 6. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006;195(1):40–9.
• 7. Wang Z, Yu D, Wang M, Wang Q, Kouznetsova J, Yang R, et al. Elabela- apelin receptor signaling pathway is functional in mammalian systems. Sci Rep 2015;5:8170.
• 8. Chng SC, Ho L, Tian J, Reversade B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Developmental cell 2013;27(6):672-80.
• 9. Devic E, Rizzoti K, Bodin S, Knibiehlern B, Audigier Y. Amino acid sequence and embryonic expression of msr/apj, the mouse homolog of Xenopus X-msr and human APJ. Mech. Dev 1999;84(1–2):199–203.
• 10. Helker C.S, Schuermann A, Pollmann C, Chng SC, Kiefer F, Reversadeet B, al. The hormonal peptide Elabela guides angioblasts to the midline during vasculogenesis. Elife 2015;4:e06726. doi: 10.7554/eLife.06726.
• 11. Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, Yano T, et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 2008;27(3):522–34.
• 12. Cox CM, Agostino SLD, Miller MK, Heimark RL, Krieget PA. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev. Biol (Basel) 2006;296(1):177–89.
• 13. Ho L, van Dijk M, Chye STJ, Messerschmidt DM, Chng SC, Ong S, et al. ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice. Science 2017;357(6352):707–13.
• 14. Deniz R, Baykus Y, Ustebay S, Ugur K, Yavuzkir Ş, Aydin S, et al. Evaluation of Elabela, apelin and nitric oxide findings in maternal blood of normal pregnant women, pregnant women with pre-eclampsia, severe pre-eclampsia and umbilical arteries and venules of newborns. J Obstet Gynaecol 2019;39(7):907-12.
• 15. American College of Obstetricians and Gynecologists. Fetal growth restriction. Obstetrics gynecol practice bulletin No. 134. Obstet Gynecol 2013;121(5):1122–33.
• 16. Eberlé D , Marousez L, Hanssens S, Knauf C, Breton C, Deruelle P, et al. Elabela and Apelin Actions in Healthy and Pathological Pregnancies. Cytokine Growth Factor Rev 2019;46:45-53.
• 17. Georgiadou D, Boussata S, Ranzijn WHM, Root LEA, Hillenius S, Bij de Weg JM, et al. Peptide Hormone ELABELA Enhances Extravillous Trophoblast Differentiation, but Placenta Is Not the Major Source of Circulating ELABELA in Pregnancy. Sci Rep 2019;9(1):19077.
• 18. Zhou L, Sun H, Cheng R, Fan X, Lai S, Deng C. ELABELA, as a Potential Diagnostic Biomarker of Preeclampsia, Regulates Abnormally Shallow Placentation via APJ. Am J Physiol Endocrinol Metab 2019;316(5):773-81.
• 19. Panaitescu B, Romero R, Gomez-Lopez N, Pacora P, Erez O, Vadillo-Ortega F, et al. ELABELA plasma concentrations are increased in women with late-onset preeclampsia. J Matern Fetal Neonatal Med 2020;33(1):5-15.
• 20. Yang X, Bian Y, Wan J, Li L, Yang P, Zhao S, et al. Variants in the 5-UTR of APELA gene in women with preeclampsia. Prenat Diagn 2019;39:308–13.
• 21. Knöfler M, Haider S, Saleh L, Pollheimer J, Gamage TKJB, James J. Human Placenta and Trophoblast Development: Key Molecular Mechanisms and Model Systems. Cell Mol Life Sci 2019;76(18):3479-96.
• 22. Nardozza LMM, Caetano ACR, Zamarian ACP, Mazzola JB, Silva CP, Marçal VM,, et al. Fetal growth restriction: current knowledge. Arch Gynecol Obstet 2017;295:1061–77.
• 23. Eberlé D, Marousez L, Hanssens S, Knauf C, Breton C, Deruelle P, et al. Elabela and Apelin Actions in Healthy and Pathological Pregnancies. Cytokine Growth Factor Rev 2019;46:45-53.